The Son Of Sevenless Homolog 1 pipeline drugs market research report outlays comprehensive information on the Son Of Sevenless Homolog 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Son Of Sevenless Homolog 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Respiratory, and Immunology which include the indications Solid Tumor, Non-Small Cell Lung Cancer, Pulmonary Fibrosis, and Systemic Sclerosis (Scleroderma). It also reviews key players involved in Son Of Sevenless Homolog 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Son Of Sevenless Homolog 1 pipeline targets constitutes close to 17 molecules. Out of which, approximately 15 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, IND/ CTA Filed, Preclinical, and Discovery stages are 2, 2, 8, and 3 respectively. Similarly, the universities portfolio in Discovery comprises 2 molecule.
Son Of Sevenless Homolog 1 overview
Son of sevenless homolog 1 (SOS1) is a SOS Ras/Rac guanine nucleotide exchange factor 1. It is a guanine nucleotide exchange factor for RAS proteins, membrane proteins that bind guanine nucleotides and participate in signal transduction pathways. Mutations in this gene are associated with gingival fibromatosis 1 and Noonan syndrome type 4.
For a complete picture of Son Of Sevenless Homolog 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
